About Halozyme Therapeutics (NASDAQ:HALO)
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:HALO
- CUSIP: 40637H10
- Web: www.halozyme.com/
- Market Cap: $2.39 billion
- Outstanding Shares: 134,013,000
- 50 Day Moving Avg: $16.21
- 200 Day Moving Avg: $13.89
- 52 Week Range: $8.18 - $18.43
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -22.56
- P/E Growth: -2.49
- Annual Revenue: $134.17 million
- Price / Sales: 17.80
- Book Value: $0.43 per share
- Price / Book: 41.44
- EBITDA: ($95,850,000.00)
- Net Margins: -91.15%
- Return on Assets: -43.18%
- Debt-to-Equity Ratio: 2.85%
- Current Ratio: 4.13%
- Quick Ratio: 3.94%
- Average Volume: 1.26 million shs.
- Beta: 2.26
- Short Ratio: 33.39
Frequently Asked Questions for Halozyme Therapeutics (NASDAQ:HALO)
What is Halozyme Therapeutics' stock symbol?
Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
How were Halozyme Therapeutics' earnings last quarter?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.02. The firm had revenue of $33.80 million for the quarter, compared to analyst estimates of $31.76 million. The business's quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.21) EPS. View Halozyme Therapeutics' Earnings History.
When will Halozyme Therapeutics make its next earnings announcement?
Where is Halozyme Therapeutics' stock going? Where will Halozyme Therapeutics' stock price be in 2017?
7 analysts have issued twelve-month price objectives for Halozyme Therapeutics' shares. Their forecasts range from $7.00 to $29.00. On average, they anticipate Halozyme Therapeutics' share price to reach $16.71 in the next twelve months. View Analyst Ratings for Halozyme Therapeutics.
Are investors shorting Halozyme Therapeutics?
Halozyme Therapeutics saw a decrease in short interest during the month of September. As of September 29th, there was short interest totalling 13,893,994 shares, a decrease of 31.6% from the September 15th total of 20,302,599 shares. Based on an average trading volume of 1,910,880 shares, the short-interest ratio is currently 7.3 days. Currently, 11.3% of the shares of the stock are sold short.
Who are some of Halozyme Therapeutics' key competitors?
Some companies that are related to Halozyme Therapeutics include Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), AveXis (AVXS), GW Pharmaceuticals PLC (GWPH), Loxo Oncology (LOXO), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Prothena Corporation PLC (PRTA), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO), Array BioPharma (ARRY), Insmed (INSM), Intercept Pharmaceuticals (ICPT), Acceleron Pharma (XLRN) and NovoCure Limited (NVCR).
Who are Halozyme Therapeutics' key executives?
Halozyme Therapeutics' management team includes the folowing people:
- Connie L. Matsui, Chairman of the Board
- Helen I Torley, President, Chief Executive Officer, Director
- Laurie D. Stelzer, Chief Financial Officer, Senior Vice President
- Harry J. Leonhardt Esq., Senior Vice President, Chief Compliance Officer, General Counsel
- Athena M. Countouriotis M.D., Senior Vice President, Chief Medical Officer
- Jean-Pierre Bizzari M.D., Independent Director
- James M. Daly, Independent Director
- Jeffrey William Henderson, Independent Director
- Kenneth J. Kelley, Independent Director
- Randal J. Kirk, Independent Director
Who owns Halozyme Therapeutics stock?
Who sold Halozyme Therapeutics stock? Who is selling Halozyme Therapeutics stock?
How do I buy Halozyme Therapeutics stock?
Shares of Halozyme Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Halozyme Therapeutics' stock price today?
MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Halozyme Therapeutics stock can currently be purchased for approximately $17.82.
Consensus Ratings for Halozyme Therapeutics (NASDAQ:HALO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.43)|
|Consensus Price Target: ||$16.71 (6.20% downside)|Consensus Price Target History for Halozyme Therapeutics (NASDAQ:HALO)
Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/16/2017||Piper Jaffray Companies||Boost Price Target||Overweight -> Overweight||$26.00 -> $29.00||N/A|
|9/15/2017||BMO Capital Markets||Boost Price Target||Market Perform||$14.00 -> $15.00||Medium|
|9/15/2017||Deutsche Bank AG||Boost Price Target||Buy||$20.00||Low|
|8/10/2017||Jefferies Group LLC||Reiterated Rating||Underperform||$6.75 -> $7.00||High|
|7/26/2017||Canaccord Genuity||Set Price Target||Buy||$16.00||High|
|6/23/2017||Barclays PLC||Reiterated Rating||Overweight||$16.00||Low|
|1/6/2017||Citigroup Inc.||Downgrade||Buy -> Neutral||N/A|
|9/8/2016||Wells Fargo & Company||Reiterated Rating||Buy||N/A|
|3/9/2016||JMP Securities||Lower Price Target||Market Outperform||$22.00 -> $20.00||N/A|
Earnings History for Halozyme Therapeutics (NASDAQ:HALO)Earnings History by Quarter for Halozyme Therapeutics (NASDAQ HALO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2017||Q2 2017||($0.25)||($0.23)||$31.76 million||$33.80 million||View||Listen|
|5/9/2017||Q1 2017||($0.25)||($0.26)||$30.79 million||$29.60 million||View||Listen|
|2/28/2017||Q416||($0.30)||($0.21)||$37.94 million||$39.00 million||View||Listen|
|11/7/2016||Q316||($0.27)||($0.23)||$34.43 million||$31.90 million||View||Listen|
|8/9/2016||Q216||($0.27)||($0.21)||$29.94 million||$33.30 million||View||N/A|
|5/9/2016||Q116||($0.20)||($0.16)||$29.65 million||$42.50 million||View||N/A|
|2/29/2016||Q415||($0.08)||$0.03||$37.06 million||$52.20 million||View||Listen|
|11/9/2015||Q315||($0.16)||($0.19)||$24.01 million||$20.80 million||View||N/A|
|8/10/2015||Q215||($0.09)||$0.02||$24.84 million||$43.40 million||View||Listen|
|5/11/2015||Q115||($0.13)||($0.12)||$19.40 million||$18.70 million||View||Listen|
|3/2/2015||Q414||($0.07)||($0.04)||$25.60 million||$30.38 million||View||N/A|
|11/10/2014||Q314||($0.14)||($0.16)||$16.50 million||$14.60 million||View||N/A|
|8/11/2014||Q214||($0.18)||($0.13)||$13.71 million||$18.40 million||View||N/A|
|5/12/2014||Q114||($0.14)||($0.22)||$13.37 million||$12.00 million||View||N/A|
|2/27/2014||Q413||($0.17)||($0.19)||$21.80 million||$12.50 million||View||N/A|
|11/8/2013||Q313||($0.15)||($0.17)||$14.62 million||$16.00 million||View||N/A|
|8/7/2013||Q2 2013||($0.13)||($0.13)||$11.29 million||$14.50 million||View||N/A|
|5/8/2013||Q1 2013||($0.15)||($0.17)||$7.05 million||$11.83 million||View||N/A|
|2/25/2013||Q4 2012||($0.16)||($0.04)||$7.32 million||$21.80 million||View||N/A|
|11/8/2012||Q312||($0.13)||($0.18)||$6.09 million||$5.33 million||View||N/A|
Earnings Estimates for Halozyme Therapeutics (NASDAQ:HALO)
2017 EPS Consensus Estimate: ($1.07)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Halozyme Therapeutics (NASDAQ:HALO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Halozyme Therapeutics (NASDAQ:HALO)
Insider Ownership Percentage: 16.80%Insider Trades by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Institutional Ownership Percentage: 85.06%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/20/2015||Laurie Stelzer||CFO||Buy||10,000||$17.24||$172,400.00|| |
|6/18/2015||Kenneth J Kelley||Director||Sell||20,000||$21.00||$420,000.00|| |
|9/16/2014||David A Ramsay||CFO||Buy||25,000||$8.90||$222,500.00|| |
|9/16/2014||Helen Torley||CEO||Buy||50,000||$8.92||$446,000.00|| |
|8/19/2014||John Stuart Patton||Director||Sell||75,000||$9.96||$747,000.00|| |
|5/15/2014||Robert Engler||Director||Sell||126,700||$7.56||$957,852.00|| |
|9/16/2013||John Stuart Patton||Director||Sell||75,000||$9.13||$684,750.00|| |
|8/19/2013||H. Michael Shepard||VP||Sell||10,000||$7.11||$71,100.00|| |
|8/14/2013||Kathryn Falberg||Director||Buy||100,000||$6.82||$682,000.00|| |
|11/29/2012||Robert Engler||Director||Buy||15,000||$5.57||$83,550.00|| |
|11/14/2012||James P Shaffer||VP||Buy||20,000||$5.22||$104,400.00|| |
|11/13/2012||Kathryn E Falberg||Director||Buy||50,000||$5.21||$260,500.00|| |
|8/27/2012||Kenneth J Kelley||Director||Buy||20,000||$5.70||$114,000.00|| |
|8/13/2012||Gregory Ian Frost||CEO||Buy||2,000||$5.50||$11,000.00|| |
Headline Trends for Halozyme Therapeutics (NASDAQ:HALO)
Latest Headlines for Halozyme Therapeutics (NASDAQ:HALO)
Loading headlines, please wait.
Halozyme Therapeutics (HALO) Chart for Sunday, October, 22, 2017